Atherogenic profiles in insulin-dependent diabetic patients and their treatment.
Longitudinal studies have shown a large excess of cardiovascular mortality in insulin-dependent diabetic patients (IDDM) as compared to non-diabetic controls. Although diabetes appears to be an independent cardiovascular risk factor, increases in total and LDL-cholesterol together with a decrease of HDL-cholesterol are more pronounced in diabetics with cardiovascular disease. The general opinion, however, derived from a large number of cross-sectional studies, is that in well-controlled IDDM lipoprotein abnormalities are modest and only slightly different from matched non-diabetic controls. Most of the studies, however, used absolute criteria based on consensus statements and do not take the internal relations of the lipoproteins into account. When atherogenic indices (such as the relationship between total cholesterol and HDL-cholesterol or the Apo A1/apo B quotient) are used, 20 to 30% of an IDDM population considered to be in clinically acceptable control have to be considered pathological. This observation is even more important since the recent Diabetes Control and Complications Trial has shown that, especially in the younger group of patients, significantly higher total cholesterol and triglycerides and lower HDL-cholesterol were observed. Especially in these patients can diet and drug intervention be the most useful in the prevention of cardiovascular disease. These data are consistent with the fact that more sophisticated techniques have previously shown atherogenic changes in the composition of the VLDL-particles and lipoprotein enrichment in apo B. Since these techniques are not easily available in the clinic one has to refer to more classical techniques and the use of above mentioned atherogenic profiles to decide treatment.
De Leeuw
I
I
Department of Endocrinology-Metabolism and Clinical Nutrition, University of Antwerp 1, Belgium.
D002784:Cholesterol / Q000097:blood*; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control*; D004041:Dietary Fats / Q000008:administration & dosage; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications* / Q000178:diet therapy / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000150:complications* / Q000178:diet therapy / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
D004041:Dietary Fats; D000960:Hypolipidemic Agents; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol